July 15, 2008
Clinical Data’s Cogenics Division to Provide Global Genotyping Solutions for Lundbeck’s Clinical Studies
Clinical Data, Inc. (NASDAQ:CLDA) a leader in the development of targeted therapeutics and predictive tests from its growing portfolio of proprietary genetic biomarkers, announced today that its Cogenics(R) division has entered into a Scientific Research & Development Agreement with H. Lundbeck A/S to support its ongoing clinical studies with genotyping solutions on a global basis. Lundbeck is an international pharmaceutical company engaged in the research and development, production, marketing and sale of drugs for the treatment of psychiatric and neurological disorders.
Under the agreement, Cogenics will employ its clinical genotyping platforms and expertise based in Morrisville, North Carolina and Bernried, Germany, to support Lundbeck's clinical studies world-wide, initially focusing on Lundbeck's Phase I studies. The term of the agreement is open-ended and the parties intend to collaborate on multiple projects going forward.
"This agreement with Lundbeck underscores Cogenics' leading position in the clinical genotyping field, and we are very pleased to form this partnership," says Michael Lutz, Global General Manager of Cogenics. "Having conducted more than 1700 genotyping studies to support clinical drug development, we are well positioned to provide value-added genotyping solutions to Lundbeck on a global basis and in a consistent, high quality manner."
For more information about Cogenics and its genomic services offerings, please call 1-877-226-4364 (U.S.) or +49 (0) 8158 - 99 85-0 (E.U.) or email [email protected]
Cogenics, a division of Clinical Data, has established itself as a leading provider of value-based genomics solutions for both the Healthcare and Life Sciences industries. These solutions span the areas of current and next generation sequencing, gene expression, clinical and non-clinical genotyping, biomanufacturing support and nucleic acid extraction and biobanking, for both research and regulated environments. Cogenics combines operations from the acquisitions of Genaissance Pharmaceuticals, Lark Technologies (in the US and UK), Icoria, Genome Express (France) and Epidauros Biotechnologie (Germany). Its customers include some of the world's most respected pharmaceutical and biotechnology companies, agencies of the US National Institutes of Health, leading government and academic researchers in the international life science community, and major agricultural companies and agencies. For more information, please visit www.cogenics.com.
About Clinical Data, Inc.
Clinical Data is a global biotechnology company unlocking the potential of molecular discovery, From Targeted Science to Better Healthcare(TM). Its PGxHealth(R) division focuses on proprietary biomarker and pharmacogenetic test development as well as targeted therapeutics to help predict drug safety and efficacy, thereby reducing health care costs and improving clinical outcomes. Its Cogenics(R) division provides genomics services to both research and regulated environments. Through these divisions, Clinical Data is leveraging advances in molecular discovery to provide tangible benefits for patients, doctors, scientists and health plans worldwide. Visit the company's website at www.clda.com for more information.
H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders. In 2007, the company's revenue was DKK 11 billion (approximately EUR 1.6 billion or USD 2.0 billion). The number of employees is approx. 5,300 globally. For more information, please visit www.lundbeck.com.
SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
This press release contains certain forward-looking information and statements that are intended to be covered by the safe harbor for forward looking statements provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)", "feel(s)", "believe(s)", "will", "may", "anticipate(s)" and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements about our ability to successfully integrate the operations, business, technology and intellectual property obtained in our acquisitions; our ability to obtain regulatory approval for, and successfully introduce our new products; our ability to expand our long-term business opportunities; financial projections and estimates and their underlying assumptions; and statements regarding future performance. All of such information and statements are subject to certain risks and uncertainties, the effects of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, but are not limited to, whether Cogenics' services will gain wide acceptance in the market; competition from pharmaceutical, biotechnology and diagnostics companies; whether Clinical Data will be able to develop or acquire additional products and attract new business and strategic partners; changes in government regulations, and changing relationships with customers, payers, suppliers and strategic partners; and those risks identified and discussed by Clinical Data in its filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward looking statements that speak only as of the date hereof. Clinical Data does not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Readers are also urged to carefully review and consider the various disclosures in Clinical Data's SEC periodic and interim reports, including but not limited to its Annual Report on Form 10-K for the fiscal year ended March 31, 2008, and Current Reports on Form 8-K filed from time to time by the Company.